GENcast: CRISPR Screens Speed Drug Discovery Efforts for Disease Intervention

Location:Home > About Us > Blogs >

GENcast: CRISPR Screens Speed Drug Discovery Efforts for Disease Intervention



Speed and accuracy are qualities that all scientists look for in their experiments, and with genome engineering studies becoming ever more ubiquitous, these attributes are more critical than ever. Large scale gene editing assays need to be checked quickly for clones that have the appropriate genotype. Compared with more traditional technologies, CRISPR screening has higher specificity to its genomic target, which means investigators can get a much cleaner signal from their samples. As attention toward cancer cell behavior in various microenvironments of the body has been growing, so too has interest in using CRISPR screening to find the underlying genes responsible for tumor growth and differentiation.


In this GENcast, our panelists will discuss how some of the various challenges and approaches to CRISPR screening. Moreover, we will discuss the use of in vivo CRISPR screens for cancer and other human disease. Finally, our panelists will tell us how they see the genome-editing field evolving and what services are available to streamline the workflows for laboratory researchers and clinal investigators. Take a listen!



Ubigene Biosciences is co-founded by biological academics and elites from China, the United States, and France. We are located in Guangzhou Science City, which serves as a global center for high technology and innovation. Ubigene Biosciences has 1000㎡ office areas and laboratories, involving genome editing, cell biology technology, and zebrafish research. We provide products and services for plasmids, viruses, cells, and zebrafish. We aim to provide customers with better gene-editing tools for cell or animal research.

We developed CRISPR-U™ and CRISPR-B™(based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, CRISPR-U™ and CRISPR-B™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo. 

Genome Editing Platform
——Focusing on the Application of CRISPR-U™ and CRISPR-B™ Gene Editing Technology
1. Provides various types of gene-editing vectors for different species.
2. Provides different virus packaging services, including lentiviruses, adenoviruses and adeno-associated viruses.3. Provides high-quality services for gene knockout, point mutation and knockin cell lines

Cell Biology Platform
——Focusing on primary cell
1. Provides over 400 types of primary cells.
2. Provides culture strategies and related products for different cell types.3. Provides cell biology-related services such as cell isolation, extraction and validation.